Effect of cancer drugs in patients with metastatic colorectal cancer in terms of mortality reduction

Por M. Yu. Fedyanin, I. A. Pokataev, O. V. Sekhina, A. A. Tryakin, S. A. Tjulandin
Publicado em 2017-12-01

Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status

Por M. Yu. Fedyanin, Kh. Kh.-M. El’snukaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, M. D. Budurova, Z. Mamedli, D. V. Podluzhnyy, N. A. Kozlov, S. A. Tyulyandin
Publicado em 2018-05-01

FOLFOXIRI in patients with colon cancer and isolated non-resectable liver metastases: phase II prospective non-randomized single-center study

Por M. Yu. Fedyanin, E. M. Polyanskaya, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh.-Kh. M. Elsnukaeva, A. N. Polyakov, I. V. Sagaydak, V. D. Podluzhniy, V. A. Aliev, S. S. Gordeev, D. V. Kuzmichev, Z. Z. Mamedli, S. A. Tjulandin
Publicado em 2019-11-01

Role of adjuvant chemotherapy in patients with rectal cancer after preoperative chemoradiotherapy: results of a retrospective study

Por M. Yu. Fedyanin, Kh. Kh.-M. El’sunkaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, V. A. Aliev, D. V. Kuzmichev, Z. Z. Mamedli, M. V. Chernykh, V. V. Glebovskaya, S. I. Tkachev, N. A. Kozlov, S. A. Tjulandin
Publicado em 2018-07-01

Metastasectomy in patients with non-resectable metastatic colorectal cancer receiving chemotherapy and anti-EGFR antibodies: a prospective, non-randomized, multicenter, phase II st...

Por M. Yu. Fedyanin, L. Yu. Vladimirova, N. A. Abramova, A. E. Storozhakova, I. L. Popova, N. M. Tikhanovskaya, E. A. Kalabanova, Е. G. Panina, A. I. Arzamastseva, E. G. Rybakov, L. V. Bolotina, T. V. Ustinova, А. А. Kachmazov, I. A. Pokataev, A. A. Tryakin, O. V. Sekhina, D. A. Chekini, Kh. Kh.-M. Elsnukaeva, D. V. Podluzhniy, S. A. Tjulandin, O. I. Kit
Publicado em 2019-06-01

Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in second‑line therapy for metastatic colon cancer: a retrospective multicenter study

Por M.   Yu. Fedyanin, L.  Yu.  Vladimirova, V.  A.  Chubenko, L.   A. Zagorskaya, A.  V.  Belyaeva, O.  L.  Fakhrutdinova, S.  A.  Belukhin, A.   S. Zhabina, L.   V. Khalikova, L.  V.  Bolotina, R.   V. Orlova, F.  V.  Moiseenko, G.   Z. Mukhametshina, A.  I.  Khasanova, A.  V.  Belonogov, Kh.  S.  Musaeva, O.  Yu.  Novikova, I.  Yu.  Stradaeva, I.  L.  Popova, S.  P.  Erdniev, A.  K.  Ivanova, A.  V.  Androsova, P.  S.  Feoktistova, E.  S.  Kuzmina, E.   V. Karabina, O.  V.  Nekrasova, O.  V.  Sekhina, A.   A. Mishchenko, L.  A.  Mukova, B.  Kh.  Kertiev, G.  I.  Kosar, S.   N. Osodoeva, A.  I.  Kats, R.  R.  Malina, M.  A.  Lyadova, A.  A.  Tryakin, S.  A.  Tyulandin
Publicado em 2022-03-01